Roche will acquire BioVeris for approximately $600 million. This acquisition will expand Roche Diagnostics’ immunochemistry business from the human diagnostics field into life science research, development, patient self-testing, veterinary testing, drug discovery and development, and clinical trials. With the acquisition, Roche will own the electrochemiluminescence (ECL) technology deployed in its Elecsys product line, which gives Roche Diagnostics the opportunity to take advantage of the ...